Innovative Research

Current Location:Innovative Research

Innovative Research

The Group is fully aware that pharmaceutical companies are empowered by innovative research and development. It has determined the innovative research and development as its core strategic path and the combination of collaborative R&D and in-house R&D as the method to accelerate the pace of innovative research and development. So far the Group has participated in the equity investment of a number of R&D companies in the United Kingdom, France, the United States, Switzerland, etc. and has possessed innovative platform focused on neurological wellness, central nervous system, new approach to the treatment of infectious disease, nanomedicine therapy, acute thrombotic disease therapy, oral T-cell immunotherapy and the R&D of medicines for oncology and immunotherapy; at the same time, the Group has the assets and market rights of more than ten main innovative patented products under research in China and some Asia-Pacific countries. We will develop clinical trials and marketing plans in China based on the characteristics of each innovative patented products to bring more effective disease treatment drugs to Chinese doctors and patients.

The development process of innovative patented products (human clinical trial is ongoing/completed) (click on the product name for more details):

Product R&D Company Indication I Phase II Phase III Phase FDA/EMA
Marketing Approval Application
PoNS
(Medical Device)
Helius Medical Technologies Treatment of chronic balance deficit due to mild- to moderate- Traumatic Brain Injury(TBI)
NRL-1
(Diazepam Nasal Spray)
Neurelis, Inc Acute Repetitive Seizures
Tyroserleutide
(CMS024)
In-house R&D Primary Liver Cancer
MTD201
(octreotide)
Midatech Pharma acromegaly and neuroendocrine cancer
CF101
(Piclidenoson)
Can-Fite BioPharma Rheumatoid Arthritis,RA; Psoriasis
CF102
(Namodenoson)
Can-Fite BioPharma hepatocellular carcinoma(HCC)、non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)
XF-73
(Exeporfinium
Chloride)
Destiny Pharma Nasal decolonisation of Staphylococcus aureus (S. aureus) to prevent postoperative S. aureus infection.
BB2603
(nano-terbinafine)
Blueberry Therapeutics onychomycosis and tinea pedis
ACT017
(Biologics)
Acticor Biotech acute phase of ischemic stroke
VXM01
(Biologics)
VAXIMM AG recurrent glioblastom
MTX110
(panobinostat)
Midatech Pharma diffuse intrinsic pontine glioma